
usd oct pm et
summari compani global leader pharmaceut medic devic consum health
price-to-earnings oper ep
past perform indic futur perform reli upon
analysi prepar equiti analyst
oct pm stock trade
target price recent
chang highlight
section stock report updat
invest rationale/risk section
stock report updat shortli
latest news stori marketscop
et cfra keep hold
drop target
ep estim line
histor forward price-to-earnings averag lift
ep estim keep
ep vs beat
consensu return growth
lift top line yoy growth
sale drug sale
bolster stelara auto-immun
total sale yoy imbruvica
leukemia darzalex
myeloma brand
drop remicad
auto-immun zytiga prostat
cancer medic devic
consum kept pace though
year-to-d sale flat yoy
adjust ep growth yoy
come buyback remain neutral
expect faster organ growth
sever peer see litig risk
weigh sentiment /colin scarola
risk assess reflect benefit
product larg immun econom cycl
earn diversifi across mani product
categori hold competit advantag
health care provid custom result divers
product mix view well larg scale
strength balanc unpredict natur
 pipelin drug patent challeng well
potenti advers legal rule health care
product develop rise scrutini drug cost
 also pose threat new regul drug
price patent protect
jan ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview johnson johnson largest health care product compani world
revenu span pharmaceut medic devic consum product
segment sale develop market wide rang synthet
biolog drug import therapeut area immunolog drug
total revenu treat autoimmun diseas like crohn diseas psoriasi arthriti oncolog
drug treat tumor form cancer neurosci drug disord like
depress schizophrenia cardiovascular drug treat high blood pressur prevent
blood clot stroke
pharmaceut product highli complex difficult develop often consum sever year
billion invest dollar found ineffect late-stag human trial fail pass
regulatori approv hurdl occur take larg write-down in-process asset
exampl produc charg compani incom statement despit
failur risk spend heavili spend
goe toward acquir compani promis pipelin drug frequent reinvest new
drug need keep pipelin full potenti market drug eventu replac
exist drug time lose market share compet treatment becom obsolet due
uncertainti involv develop market success pharmaceut largest risk
earn view billion invest dollar risk never produc
profit drug compet version drug success patent challeng court
competitor cut short success drug profit lifespan one recent exampl best-sel
drug remicad sale biolog drug began lose sale due biosimilar akin
gener biolog drug approv approv biosimilar remicad sale fell
like drop even compet biosimilar
enter market anoth top-sel drug zytiga sale held patent initi
valid lengthi court battl sever gener competitor right market
gener form zytiga begin late accordingli expect zytiga sale fall precipit
medic devic segment sale sell wide rang health care product includ
wound care surgic instrument implant hip knee replac spinal implant like
pharmaceut medic devic segment also depend invest develop innov
consum segment sale sell wide varieti person care product one might find
groceri store retail pharmaci includ over-the-count medicin adult skin hair care
product babi care oral care first aid women health nutrit supplement consum
segment includ major brand-nam like band-aid listerin johnson babi care line neutrogena
aveeno skin hair care product mani well-known over-the-count medicin like tylenol pepcid
sudaf
brand-nam reput critic import success consum segment view
consum product often face sever low-pric compet product trust brand name make
big differ sale especi come health care product one put bodi
love one bodi
due import brand power consum trust think alleg reuter stori
publish decemb could meaning neg impact consum segment
well medic devic segment lesser extent report alleg disclos
fda asbesto sometim found babi powder date back
vehement deni alleg defend court relat case well put forth
major public relat campaign defend safeti babi powder product regardless
think report like come next year subject whether report
merit think materi risk issu news less trust
consum brand
corpor strategi despit industri lead scale highli innov view seek
maintain leadership posit aggress fund new product develop spend
total billion repres sale major devot drug develop
januari nearli late-stag clinic drug trial underway fda file review
process mani trial expand treatment indic exist drug also expect
compani launch least seven novel drug end
although intern growth key object also pursu strateg acquisit spend
 recent larg acquisit includ
billion june retain actelion market drug mainli treat hypertens late stage
compound divest discoveri stage oper spin-off
financi trend total revenu grew equat compound
annual growth rate compound-annual-growth-rate period adjust ep grew
compound-annual-growth-rate grown ep faster sale mainli margin improv
revenu mix shift toward higher margin pharmaceut late adjust oper margin
improv around also return materi capit sharehold
repurchas dividend combin total
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu usd
neutral sinc octob technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
outlook sub-industri
next year neutral expect
modest revenu growth driven
slowdown novel drug approv
potenti new price regul
neg partial off-set upcom
favor period patent expir
also expect major gener maker continu
struggl lower cost foreign competit
keep pressur profit margin
banner year new brand
drug fda see slowdown
total novel drug
approv fda
signific surg compar approv
new brand help drive
ebitda growth sub-industri
versu averag
new drug launch appear
slow howev
approv year august
period also observ
yoy declin spend
like portend effort maintain margin
sluggish revenu growth year ahead
pharmaceut also face increas risk
new drug price rule view
accord wall street journal studi
govern health system develop
countri like england norway canada
often pay less major drug
poll indic american feel drug
cost unreason believ
dynam increas pressur drug
maker curtail price hike politician
enact polici lower drug cost
voter accordingli sever new propos
lower drug price emerg side
isl recent month trump
administr announc explor base
medicar drug price intern index
hous democrat introduc bill
would allow medicar directli negoti
price drug maker senat
republican propos lower
out-of-pocket maximum medicar drug
plan shift cost burden
drug maker none propos
current enough support becom law
view see polit parti
increas focu control drug cost
signific risk weigh outlook
sub-industri
balanc neg factor face
brand drug maker expect
upcom favor period patent
expir typic biggest
revenu headwind base data
evaluatepharma annual global drug sale
risk expir patent averag
total forecast
drop fewer
patent cliff year ahead
major posit brand drug revenu
beyond brand firm make lion
share sub-industri market cap outlook
major gener maker neg think
india-bas gener maker continu
take market share develop nation
firm due lower product cost
estim india-bas produc oper
averag gross margin
versu top western gener
foreign firm
drop broader composit
year-to-d septemb
pharmaceut index
gain
base index
five-year market price perform oct
note sector sub-industri inform base
past perform indic futur perform
reli upon
compani
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
analyst research note compani news
et cfra keep hold opinion share johnson johnson
drop target ep estim line
histor forward price-to-earnings averag lift ep estim
keep ep vs beat
consensu return growth lift top line yoy
growth sale drug sale bolster
stelara auto-immun total sale yoy imbruvica
leukemia darzalex myeloma brand
impress off-set biosimilar/gener driven drop remicad
auto-immun zytiga prostat cancer medic devic
consum kept pace though year-to-d sale
yoy come buyback remain neutral
expect faster organ growth sever peer see litig risk
weigh sentiment /colin scarola
pm et cfra lower opinion johnson johnson share hold
buy drop target ep
estim -- five-year averag forward price-to-earnings expect neg
impact recent alleg cancer-caus asbesto certain product
maintain ep estim lower
report surfac today alleg disclos fda
asbesto sometim found babi powder ingredi date back
vehement deni either way expect signific
damag unfold valuabl brand name consum product
medic devic built decad consum medic
devic segment gener profit brand name accompani
consum trust critic success see today news potenti
impact sale everyth babi shampoo prosthet hip given
elev risk longer feel share attract recent price /colin
et cfra keep hold opinion share johnson johnson
keep target ep estim line
histor forward price-to-earnings averag ep estim
maintain ep vs consensu
mark slow growth across segment organ revenu growth
yoy full-year pharmaceut revenu
experienc sharpest slowdown yoy growth vs
full-year segment saw oncolog total revenu grow
impress yoy also saw declin remicad
autoimmun due biosimlar entri xarelto stroke market share loss
stroke drug eliqui bottom line non-gaap ep grew
yoy benefit one-tim non-oper gain sale exclud
gain estim adjust pre-tax incom per share grew yoy remain
neutral share expect earn growth outpac peer
lower target peer averag
ep estim view exist drug portfolio
pipelin posit ep vs slightli forecast
lower ep estim slower growth
medic devic segment initi ep estim modest
sale growth quarter yoy led pharma segment
increas oncolog group particularli strong perform within pharma
grow sale yoy total expect pharma continu
drive growth come year especi stelara imbruvica
darzalex increas sale yoy improv
margin mix think robust demand drug overcom potenti
gener competit zytiga total sale next year slower growth
medic devic consum segment grew sale yoy
pm et cfra keep hold opinion share johnson johnson
rais target price ep
estim -- in-lin histor forward price-to-earnings averag keep
ep estim rais ep
vs consensu revenu flat yoy
sale growth yoy off-set declin yoy medic
devic consum respect immunolog treatment revenu
oncolog drug show strong sale growth yoy
respect despit flat revenu quarter adjust pre-tax incom per
share declin yoy driven ramp spend grew
yoy think invest heavili futur growth wise
sever key drug face gener biosimilar competit expect
free cash flow return capit remain strong think share
current near fair valu /colin scarola
et cfra keep hold opinion share johnson johnson
rais target price ep
estim -- slightli five-year averag price-to-earnings multipl expect
modest slowdown growth next year ep vs
slightli consensu rais ep estim
cy revenu growth modest
acceler aid roughli acquisit execut
sinc start despit materi sale growth slow
yoy sharp slowdown yoy first month much
slowdown relat slow pharma sale total grew
yoy vs first month mainli driven gener
competit key oncolog drug zytiga whose growth slow
expect free cash flow return capit remain strong
think like slowdown growth warrant conserv valuat
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
